Development of Cardiomyocyte-Derived Extracellular Vesicles as a Therapeutic Agent for COVID-19-Related Cardiac Inflammation and Damage

• 研究課題/領域番号: 25K11327
• 研究種目: 基盤研究(C)
• 配分区分: 基金
• 応募区分: 一般
• 審査区分: 小区分53020:循環器内科学関連
• 研究機関: 慶應義塾大学
• 研究代表者: PrietoVila Marta 慶應義塾大学, 薬学部(芝共立), 講師 (40804646)
• 研究期間 (年度): 2025-04-01 – 2028-03-31
• 研究課題ステータス: 交付 (2025年度)
• 配分額: 6,500千円 (直接経費: 5,000千円、間接経費: 1,500千円); 2027年度: 1,950千円 (直接経費: 1,500千円、間接経費: 450千円); 2026年度: 2,210千円 (直接経費: 1,700千円、間接経費: 510千円); 2025年度: 2,340千円 (直接経費: 1,800千円、間接経費: 540千円)
• キーワード: cardiac diseases / COVID-19 / inflamation / extracelular vesicles / no-cell therapy

研究開始時の研究の概要

We aim to ameliorate COVID-19-associated cardiac damage. To do so, we will evaluate the anti-inflammatory and antifibrotic effects of cardiomyocytes-EVs in vitro using human macrophages and cardiac fibroblasts. Following, we will test their effect in a chronic inflammation mouse model. We will assess cytokine profiles, macrophage activation, fibrotic area, and cardiac function. Additionally, we will analyze EV internalization and the role of surface proteins to investigate their specificity toward cardiac tissue to explore their application as a targeted drug delivery system for the heart.